Articles published by XBiotech Inc.
![](https://ml.globenewswire.com/media/a7b2e5dd-665a-4306-a53a-32391bdf6c79/small/xbiotech-logo.jpg)
![](https://ml.globenewswire.com/media/a7b2e5dd-665a-4306-a53a-32391bdf6c79/small/xbiotech-logo.jpg)
![](https://ml.globenewswire.com/media/a7b2e5dd-665a-4306-a53a-32391bdf6c79/small/xbiotech-logo.jpg)
![](https://ml.globenewswire.com/media/a7b2e5dd-665a-4306-a53a-32391bdf6c79/small/xbiotech-logo.jpg)
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
September 26, 2023
From XBiotech Inc.
Via GlobeNewswire
Tickers
XBIT
![](https://ml.globenewswire.com/media/a7b2e5dd-665a-4306-a53a-32391bdf6c79/small/xbiotech-logo.jpg)
![](https://ml.globenewswire.com/media/a7b2e5dd-665a-4306-a53a-32391bdf6c79/small/xbiotech-logo.jpg)
![](https://ml.globenewswire.com/media/a7b2e5dd-665a-4306-a53a-32391bdf6c79/small/xbiotech-logo.jpg)
![](https://www.globenewswire.com/Content/Images/intrado.png)
![](https://ml.globenewswire.com/media/a7b2e5dd-665a-4306-a53a-32391bdf6c79/small/xbiotech-logo.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.